Effect of Genetic Polymorphism on Capecitabine-Induced Toxicity in Egyptian Cancer Patients
Ain Shams University
80 participants
Apr 1, 2024
OBSERVATIONAL
Conditions
Summary
The goal of this observational study is to study the effect of a single nucleotide polymorphism in the CES1 gene (rs2244613) on capecitabine-induced toxicity in Egyptian cancer patients. This study will help in understanding the interindividual variability in the CES1 gene and the effect of a single nucleotide polymorphism in this gene (rs2244613) on capecitabine-induced toxicity in participants already taking capecitabine-based chemotherapy as part of their regular medical care.
Eligibility
Inclusion Criteria3
- Patients with breast or colorectal cancer receiving capecitabine-based chemotherapy
- Age \> 18 years
- ECOG PS 0-2.
Exclusion Criteria6
- Patients treated with irinotecan
- Lack of physical integrity of the upper gastrointestinal tract
- Patients with malabsorption syndrome
- Patients having inability to take oral medication
- Patients with poor performance status
- Patients with chronic diarrhea as ulcerative colitis or Crohn's disease
Interventions
Participants receiving capecitabine in an oral dose of 1,000-1,250 mg/m2 twice daily for the first 14 days of each 21-day cycle.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06765252